JP7712922B2 - 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト - Google Patents

炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト

Info

Publication number
JP7712922B2
JP7712922B2 JP2022526326A JP2022526326A JP7712922B2 JP 7712922 B2 JP7712922 B2 JP 7712922B2 JP 2022526326 A JP2022526326 A JP 2022526326A JP 2022526326 A JP2022526326 A JP 2022526326A JP 7712922 B2 JP7712922 B2 JP 7712922B2
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
composition
independently selected
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022526326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554389A (ja
JP2022554389A5 (https=
Inventor
フェルダ チェビクバシュ
アシュリー ジャービス
ローラ グリーブ
ニーナ コネリー ウルシニョバ
リッキー ケイン
ウェイ ツン ヤウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of JP2022554389A publication Critical patent/JP2022554389A/ja
Publication of JP2022554389A5 publication Critical patent/JP2022554389A5/ja
Priority to JP2025117223A priority Critical patent/JP2025148482A/ja
Application granted granted Critical
Publication of JP7712922B2 publication Critical patent/JP7712922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022526326A 2019-11-05 2020-11-05 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト Active JP7712922B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117223A JP2025148482A (ja) 2019-11-05 2025-07-11 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962931183P 2019-11-05 2019-11-05
US62/931,183 2019-11-05
US201962931698P 2019-11-06 2019-11-06
US62/931,698 2019-11-06
US202063046461P 2020-06-30 2020-06-30
US63/046,461 2020-06-30
PCT/US2020/059201 WO2021092240A1 (en) 2019-11-05 2020-11-05 Mrgprx2 antagonists for the treatment of inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117223A Division JP2025148482A (ja) 2019-11-05 2025-07-11 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト

Publications (3)

Publication Number Publication Date
JP2022554389A JP2022554389A (ja) 2022-12-28
JP2022554389A5 JP2022554389A5 (https=) 2024-05-21
JP7712922B2 true JP7712922B2 (ja) 2025-07-24

Family

ID=73646519

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022526326A Active JP7712922B2 (ja) 2019-11-05 2020-11-05 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト
JP2025117223A Pending JP2025148482A (ja) 2019-11-05 2025-07-11 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117223A Pending JP2025148482A (ja) 2019-11-05 2025-07-11 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト

Country Status (8)

Country Link
US (3) US20230029266A1 (https=)
EP (1) EP4054554A1 (https=)
JP (2) JP7712922B2 (https=)
CN (1) CN114845709B (https=)
AU (1) AU2020380395A1 (https=)
CA (1) CA3159766A1 (https=)
IL (1) IL292690A (https=)
WO (1) WO2021092240A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2019183587A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2020154571A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2021092240A1 (en) 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists for the treatment of inflammatory disorders
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
TWI904906B (zh) 2020-08-24 2025-11-11 美商達薩瑪治療公司 Sarm1之抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
WO2025002360A1 (zh) * 2023-06-30 2025-01-02 北京普祺医药科技股份有限公司 一种mrgprx2拮抗剂、药物组合物以及其用途
WO2025042736A1 (en) 2023-08-18 2025-02-27 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025066935A1 (en) * 2023-09-28 2025-04-03 Hepaitech (Beijing) Biopharma Technology Co., Ltd. Compounds, compositions and methods thereof
WO2025130765A1 (en) * 2023-12-18 2025-06-26 Hepaitech (Beijing) Biopharma Technology Co., Ltd. Compounds, compositions and methods thereof
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
KR20250121245A (ko) * 2024-02-02 2025-08-12 삼진제약주식회사 MRGPRX2 (Mas-related G-protein coupled receptor member X2) 길항제로서 신규 화합물 및 이를 포함하는 약학적 조성물
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
JP2026009006A (ja) * 2024-07-01 2026-01-19 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途
WO2026035726A1 (en) * 2024-08-07 2026-02-12 Arcus Biosciences, Inc. Piperidylurea compounds and methods of use thereof
US12612396B1 (en) * 2024-11-20 2026-04-28 Dewpoint Therapeutics, Inc. Modulators of beta catenin and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
JP2017530960A (ja) 2014-09-23 2017-10-19 ミッション・セラピューティクス・リミテッド 新規化合物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493555A (en) 1966-03-23 1970-02-03 Nepera Chem Co Inc 3-phenylazo-2,6-pyridyl dicyclopropane-carboxamide
US4152442A (en) 1975-06-05 1979-05-01 Lilly Industries Limited Certain acylamino-oxa (or thia) diazoles in treatment of hypersensitivity conditions
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
PH22076A (en) * 1983-08-25 1988-05-20 Daiichi Seiyaku Co Benzocycloalkane derivative
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JPH0717589B2 (ja) * 1990-01-22 1995-03-01 ファイザー製薬株式会社 新規１，３―ジカルボニル化合物およびその組成物
CH681383A5 (https=) 1990-04-11 1993-03-15 Alusuisse Lonza Services Ag
US5290943A (en) 1991-02-21 1994-03-01 Ichikawa Gosei Chemical Co., Ltd. Method of producing 2-acyl amino 5-halogenopyridine compounds
JPH05201981A (ja) 1991-08-06 1993-08-10 Ichikawa Gosei Kagaku Kk ２−アミノ−３−ニトロ−５−ハロゲノピリジン類の製造方法
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
JP2006522744A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
ZA200602755B (en) 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
EP1696915A1 (en) 2003-12-19 2006-09-06 Pfizer, Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
JP2008510726A (ja) * 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
CN1736989A (zh) 2004-08-20 2006-02-22 中国科学院大连化学物理研究所 一种杂环菊酯类化合物及其在除草杀菌方面的应用
KR20080063865A (ko) 2005-11-28 2008-07-07 에프. 호프만-라 로슈 아게 다이아실글리세롤 아실전이효소(ｄｇａｔ)의 저해제
WO2007086584A1 (ja) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
CA2691214A1 (en) * 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2008063625A2 (en) 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
EP2125799A1 (en) * 2007-02-28 2009-12-02 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2010013705A (es) 2008-06-13 2011-02-25 Bayer Cropscience Ag Nuevas amidas y tioamidas heteroaromaticas como plaguicidas.
WO2011074658A1 (ja) 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
EP2545037A1 (en) 2010-03-10 2013-01-16 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
DE102010012594A1 (de) * 2010-03-23 2011-09-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten
KR101688978B1 (ko) * 2010-08-18 2016-12-26 중앙대학교 산학협력단 신규한 2-아미노 티아졸 유도체 및 이를 포함하는 항암용 조성물
PT2673285T (pt) 2010-12-09 2017-10-19 Wockhardt Ltd Resumo
DE102011083271A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
CA2850551A1 (en) 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
FR2982261B1 (fr) 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
WO2014040243A1 (zh) * 2012-09-12 2014-03-20 湖南有色凯铂生物药业有限公司 N-取代苯基-n'-取代杂环脲类化合物及其作为抗癌药物的应用
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
ES2670517T3 (es) 2013-01-30 2018-05-30 Sumitomo Chemical Company, Limited Compuesto de amida, un agente de control de plagas de artrópodos y un método para controlar las plagas de artrópodos
WO2014125426A1 (en) 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US9758505B2 (en) 2014-02-12 2017-09-12 Iteos Therapeutics 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
CN104876878B (zh) * 2014-02-27 2018-04-27 中国科学院广州生物医药与健康研究院 5-芳基酚-2烷基取代脲苯并咪唑类化合物及其应用
US10253023B2 (en) 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2016160938A1 (en) * 2015-04-02 2016-10-06 Abbvie Inc. N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators
WO2017064068A1 (en) * 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
AR106679A1 (es) 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
CN105924387A (zh) 2016-04-28 2016-09-07 西安交通大学 一种具有抗肿瘤活性的双芳基脲化合物及其制备方法和应用
IL266181B2 (en) * 2016-11-03 2024-04-01 Corvus Pharmaceuticals Inc Compounds and methods for modulating interleukin-2-inducible t-cell kinase
WO2018114783A1 (en) 2016-12-23 2018-06-28 Bayer Pharma Aktiengesellschaft Tetrazole containing compounds
CA3055194A1 (en) 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
UY37957A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3498694A1 (en) 2017-12-12 2019-06-19 Medibiofarma, S.L. New benzamide derivatives as ppar-gamma modulators
CN108451967B (zh) * 2018-06-04 2020-06-19 西安交通大学 克拉霉素在制备抗类过敏反应药物中的应用
CN108619183A (zh) * 2018-06-04 2018-10-09 西安交通大学 一种白芷中香豆素类化合物的简单提取方法及其应用
WO2021092240A1 (en) 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists for the treatment of inflammatory disorders
CN114901280B (zh) 2019-11-05 2025-05-27 德米拉公司 MrgprX2拮抗剂及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
JP2017530960A (ja) 2014-09-23 2017-10-19 ミッション・セラピューティクス・リミテッド 新規化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY(STN) [online]，[検索日:2025年1月7日]

Also Published As

Publication number Publication date
US20230029266A1 (en) 2023-01-26
CN114845709A (zh) 2022-08-02
JP2025148482A (ja) 2025-10-07
WO2021092240A1 (en) 2021-05-14
CN114845709B (zh) 2024-10-01
JP2022554389A (ja) 2022-12-28
US20260027089A1 (en) 2026-01-29
EP4054554A1 (en) 2022-09-14
US12502380B2 (en) 2025-12-23
US20250057816A1 (en) 2025-02-20
IL292690A (en) 2022-07-01
AU2020380395A1 (en) 2022-05-26
CA3159766A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
JP7712922B2 (ja) 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト
JP7827911B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
JP7787811B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
CN103403001B (zh) 杂环衍生物及其在神经性疾病治疗中的应用
TW201734012A (zh) 經取代２－苯基－３－（哌甲基）咪唑并吡啶類及其用途
EP2785713A1 (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP2019521170A (ja) 置換ジアザヘテロ−二環式化合物およびそれらの使用
AU2007218596A1 (en) Stabilized pharmaceutical composition
JP2018538296A (ja) 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用
CN111670189A (zh) 对rsv具有活性的环烷基取代的吡唑并嘧啶
WO2021218992A1 (zh) 取代的吡咯烷类化合物及其在药物中的应用
CN103998446B (zh) 新的三氟甲基‑噁二唑衍生物及它们在治疗疾病中的应用
HK40074244A (en) Inhibitors of adrenoreceptor adrac2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250711

R150 Certificate of patent or registration of utility model

Ref document number: 7712922

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150